Micrometastasis: Detection methods and clinical importance

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 397-419

  Balic, Marija ^a   Williams, Anthony ^b   Dandachi, Nadia ^a   Cote, Richard J ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; breast cancer; cancer stem cells; circulating tumor cells (CTC); colorectal cancer; CTC enrichment; disseminated tumor cells (DTC); membrane microfilter device; Metastasis; microfiltration; prostate cancer

Indexed keywords

ANTIBODY; MESSENGER RNA;

ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CELL DENSITY; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DISSEMINATED TUMOR CELL; DNA DETERMINATION; FLOW CYTOMETRY; LUNG CANCER; LYMPH NODE METASTASIS; MICROMETASTASIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION;

HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM MICROMETASTASIS; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 82955193256     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0161     Document Type: Article

References (196)

1. R. J. Cote, Occult metastases: real harm of false alarm? J Thor and Cardivasc Surg 126(2August 2003), 332-333.
2. R. J. Cote, P. P. Rosen and T. B. Hakes et al. , Monoclonal antibodies detect occult breast carcinoma metastases in bone marrowof patientswith early-stage disease, AmJ Surg Pathol 12 (1988), 333.
3. G. Schlimok, I. Funke and B. Holzman et al. ,Micrometastatic cancer cells in bone marrow: In vitro detection with anticytokeratin and in vivo anti-17-1A monoclonal antibody, Proc Natl Acad Sci USA 84 (1987), 8672.
4. K. Pantel and R. H. Brakenhoff, Dissecting the metastatic cascade, Nat Rev Cancer 4(6Jun 2004), 448-456.
5. D. P. Dearnaley, J. P. Sloan and S. Imrie et al. , Detection of isolatedmammary carcinoma cells inmarrowof patientswith primary breast cancer, J R Soc Med 76 (1983), 359.
6. W. H. Redding, P. Monaghan and S. F. Imrie, Detection of icrometastases in patients with primary breast cancer, Lancet (1983), 1271-1274.
7. J. Y. Pierga, C. Bonneton, A. Vincent-Salomon, P. de Cremoux, C. Nos, N. Blin et al. , Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients, Clin Cancer Res 10(415 Feb 2004), 1392-1400.
8. S. M. Trocciola, S. Hoda, M. P. Osborne, P. J. Christos, H. Levin, D. Martins et al. , Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? J Am Coll Surg 200(5May 2005), 720-725; discussion 5-6.
9. A. M. Neville, Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important, Ann Onc 2 (1989), 13-14.
10. K. Pantel, G. Schlimok, M. Angstwurm, D. Weckermann, W. Schmaus, H. Gath et al. , Methodological analysis of immunocytochemica screening for disseminated epithelial tumor cells in bone marrow, J Hematother 3 (1994), 165-173.
11. S. Braun, K. Pantel, P. Muller, W. Janni, F. Hepp, C. R. Kentenich et al. , Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer, N Engl J Med 342(824 Feb 2000), 525-533.
12. S. Braun and B. Naume, Circulating and disseminated tumor cells, J Clin Oncol 23(82005), 1623-1626.
13. O. Lara, X. Tong, M. Zborowski and J. J. Chalmers, Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation, Exp Hematol 32(10Oct 2004), 891-904.
14. R. Rosenberg, R. Gertler, J. Friederichs, K. Fuehrer, M. Dahm, R. Phelps et al. , Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood, Cytometry 49(41 Dec 2002), 150-158.
15. T. E. Witzig, B. Bossy, T. Kimlinger, P. C. Roche, J. N. Ingle, C. Grant et al. , Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy, Clin Cancer Res 8(5May 2002), 1085-1091.
16. B. Naume, E. Borgen, J. M. Nesland, K. Beiske, E. Gilen, A. Renolen et al. , Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation, Int J Cancer 78 (1998), 556-560.
17. B. Naume, E. Borgen, K. Beiske, T. K. Herstad, G. Ravnas, A. Renolen et al. , Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood, J Hematother 6(2Apr 1997), 103-114.
18. P. T. Went, A. Lugli, S. Meier, M. Bundi, M. Mirlacher, G. Sauter et al. , Frequent EpCam protein expression in human carcinomas, Hum Pathol 35(1Jan 2004), 122-128.
19. J. Gottschalk, M. Korves, B. Skotzek-Konrad, S. Goebel and J. Cervos-Navarro, Dysembryoplastic neuroepithelial microtumor in a 75-year-old patient with long-standing epilepsy, Clin Neuropathol 12(3May-Jun 1993), 175-178.
20. U. Woelfle, E. Breit, K. Zafrakas, M. Otte, F. Schubert, V. Muller et al. , Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients, J Immunol Methods 300(1-2May 2005), 136-145.
21. M. Raynor, S. A. Stephenson, D. C. Walsh, K. B. Pittman and A. Dobrovic, Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells, BMC Cancer 2 (24 May 2002), 14.
22. P. de Cremoux, J. M. Extra, M. G. Denis, J. Y. Pierga, E. Bourstyn, C. Nos et al. , Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction, Clin Cancer Res 6(8Aug 2000), 3117-3122.
23. E. Racila, D. Euhus, A. J. Weiss, C. Rao, J. McConnell, L. W. Terstappen et al. , Detection and characterization of carcinoma cells in the blood, Proc Natl Acad Sci USA 95 (1998), 4589-4594.
24. G. Vona, A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schutze et al. , Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells, Am J Pathol 156(1Jan 2000), 57-63.
25. H. Mohamed, L. D. McCurdy, D. H. Szarowski, S. Duva, J. N. Turner and M. Caggana, Development of a rare cell fractionation device: application for cancer detection, IEEE Trans Nanobioscience 3(4Dec 2004), 251-256.
26. H. J. Kahn, A. Presta, L. Y. Yang, J. Blondal, M. Trudeau, L. Lickley et al. , Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage, Breast Cancer Res Treat 86(3Aug 2004), 237-247.
27. R. L. Fleischer, H. W. Alter, S. C. Furman, P. B. Price and R. M. Walker, Particle track etching, Science 178(5820 Oct 1972), 255-263.
28. S. Zheng, H. Lin, J. Q. Liu, M. Balic, R. Dtar, R. J. Cote et al. , Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells, J Chromatogr A 1162(231 Aug 2007), 154-161.
29. S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus et al. , Isolation of rare circulating tumour cells in cancer patients by microchip technology, Nature 450(717320 Dec 2007), 1235-1239.
30. Y. Huang, J. Yang, X. B. Wang, F. F. Becker and P. R. Gascoyne, The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretic fieldflow- fractionation, J Hematother Stem Cell Res 8(5Oct 1999), 481-490.
31. J. Cheng, E. L. Sheldon, L. Wu and M. J. Heller and J. P. O'Connell, Isolation of cultured cervical carcinoma cells mixed with peripheral blood cells on a bioelectronic chip, Anal Chem 70(111 Jun 1998), 2321-2326.
32. M. P. Osborne, G. Y. Wong and S. Asina, al. e. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow, Cancer Res 51 (1991), 2706.
33. M. P. Osborne, S. Asina and G. Y. Wong, Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system, Cancer Res 49 (1989), 2510.
34. G. Ellis, M. Fergusson and E. Yamanaka, Monoclonal antibodies for detection of occult carcinoma cells in bonemarrow of breast cancer patients, Cancer 63 (1989), 2509-2514.
35. R. J. Cote, P. P. Rosen, M. L. Lesser, L. J. Old and M. P. Osborne, Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases, J Clin Oncol 9(101991), 1749-1756.
36. H. Silly, H. Samonigg, H. Stoger, H. P. Brezinschek and M. Wilders-Trusching, Micrometastatic tumor cells in bonemarrow in colorectal carcinoma, Lancet 340 (1992), 1288.
37. G. Schlimok, I. Funke, B. Bock, S. B, J. Witte and G. Riethmuller, Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance, J Clin Oncol 8 (1990), 831-837.
38. F. Lindeman, G. Schlimok, P. Dirschedl, J. Witte and G. Reithmuller, Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients, Lancet 340 (1992), 685-689.
39. D. P. J. Wood, E. R. Banks, S. Humphreys and V. M. Rangnekar, Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in the bone marrow, J Histochem Cytochem 42 (1994), 505-511.
40. R. Oberneder, R. Riesenberg and M. Kriegmair, al. e. Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer, Urol Res 22 (1994), 3-8.
41. J. G. Moreno, C. M. Croce and R. Fischer, al. e. Detection of hematogenous micrometastases in patients with prostate cancer, Cancer Res 52 (1992), 6110-6112.
42. J. L. Mansi, W. E. Mesker and M. T, al. e. Automated screening for micrometastases in bone marrow smears, J Immunol Methods 112 (1988), 105.
43. P. R. Bretton, M. R. Melamed,W. R. Fair and R. J. Cote, Detection of occult micrometastases in the bonemarrow of patients with prostate carcinoma, Prostate (1994), 108-14.
44. K. Pantel, J. R. Izbicki, M. Angswurm, S. Braun, B. Passlick, O. Karg et al. , Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer, Cancer Res 53(51993), 1027-1031.
45. K. Pantel, J. Isbicki and B. Passlick, al. e. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases, Lancet 347 (1996), 649-653.
46. R. C. F. Leonard, L. W. Duncan and F. G. Hay, Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer, Cancer Res 50 (1990), 6545-6548.
47. A. J. Frew, N. Ralkaier, A. K. Ghosh, K. C. Gatter and D. Y. Mason, Immunohistochemistry in the detection of bone marrow micrometastases in patients with primary lung cancer, Br J Cancer 53 (1986), 555-556.
48. R. J. Cote, E. J. Beattie, B. Chaiwun, S. R. Shi, J. Harvey, S. C. Chen et al. , Detection of occult bone marrow metastases in patients with operable lung carcinoma, Ann Surg 222 (1995), 415-425.
49. K. Boo and S. A. Cheng, A morphological and immunohistochemical study of plasma cell proliferative lesions, Malasian J of Pathol 14 (1992), 45-48.
50. B. Chaiwun, A. D. Saad and S. -C. Chen, al. e. Immunohistochemical detection of occult carcinoma in bone marrow and blood, Diag Oncol 2 (1992), 267.
51. X. Gao and S. Nie, Molecular profiling of single cells and tissue specimens with quantum dots, Trends Biotechnol 21(9Sep 2003), 371-373.
52. H. Arya, Z. Kaul, R. Wadhwa, K. Taira, T. Hirano and S. C. Kaul, Quantum dots in bio-imaging: Revolution by the small, Biochem Biophys Res Commun 329(422 Apr 2005), 1173-1177.
53. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara et al. , Most of early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype, Clin Cancer Res 12(192006), 5615-5621.
54. K. D. Bauer, J. de la Torre-Bueno, I. J. Diel, D. Hawes, W. J. Decker, C. Priddy et al. , Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging, Clin Cancer Res 6(92000), 3552-3559.
55. K. D. Bauer, J. de la Torre-Bueno, I. J. Diel, D. Hawes, W. J. Decker, C. Priddy et al. , Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging, Clin Cancer Res 6(9Sep 2000), 3552-3559.
56. K. Pantel, R. J. Cote and O. Fodstad, Detection and clinical importance of micrometastatic disease, J Natl Cancer Inst 91(137 Jul 1999), 1113-1124.
57. T. Hashimoto, Y. Kobayashi, Y. Ishikawa, S. Tsuchiya, S. Okumura, K. Nakagawa et al. , Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases, Cancer Res 60(2215 Nov 2000), 6472-6478.
58. N. Hayashi, I. Ito, A. Yanagisawa, Y. Kato, S. Nakamori, S. Imaoka et al. , Genetic diagnosis of lymph-node metastasis in colorectal cancer, Lancet 345(896020 May 1995), 1257-1259.
59. J. S. Hsieh, S. R. Lin, M. Y. Chang, F. M. Chen, C. Y. Lu, T. J. Huang et al. , APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance, Am Surg 71(4Apr 2005), 336-343.
60. H. M. Muller, A. Widschwendter, H. Fiegl, L. Ivarsson, G. Goebel, E. Perkmann et al. , DNA methylation in serum of breast cancer patients: an independent prognostic marker, Cancer Res 63(2215 Nov 2003), 7641-7645.
61. A. Ring, I. E. Smith andM. Dowsett, Circulating tumour cells in breast cancer, Lancet Oncol 5(2Feb 2004), 79-88.
62. T. J. Pelkey, H. F. Frierson, Jr. and D. E. Bruns, Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors, Clin Chem 42(9Sep 1996), 1369-1381.
63. L. Xi, D. G. Nicastri, T. El-Hefnawy, S. J. Hughes, J. D. Luketich and T. E. Godfrey, Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers, Clin Chem 53(7Jul 2007), 1206-1215.
64. P. J. Bostick, S. Chatterjee, D. D. Chi, K. T. Huynh, A. E. Giuliano, R. J. Cote et al. , Limitations of specific reversetranscriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients, J Clin Oncol 16(81998), 2632-2640.
65. B. Smith, P. Selby, J. Southgate, K. Pittman, C. Bradley and G. E. Blair, Detection of melanoma cells in peripheral blood bymeans of reverse transcriptase and polymerase chain reaction, Lancet 338(877716 Nov 1991), 1227-1229.
66. M. B. Wallace, M. Block, B. J. Hoffman, R. H. Hawes, G. Silvestri, C. E. Reed et al. , Detection of telomerase expression in mediastinal lymph nodes of patients with lung cancer, Am J Respir Crit Care Med 167(1215 Jun 2003), 1670-1675.
67. M. Sakaguchi, A. Virmani, M. W. Dudak, G. N. Peters, A. M. Leitch, H. Saboorian et al. , Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer, Ann Surg Oncol 10(2Mar 2003), 117-125.
68. H. J. Blaheta, U. Ellwanger, B. Schittek, K. Sotlar, E. MacZey, H. Breuninger et al. , Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma, J Invest Dermatol 114(4Apr 2000), 637-642.
69. M. J. Slade, A. Singh, B. M. Smith, G. Tripuraneni, E. Hall, C. Peckitt et al. , Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years, Int J Cancer 114(110 Mar 2005), 94-100.
70. R. Q. Wharton, S. K. Jonas, C. Glover, Z. A. Khan, A. Klokouzas, H. Quinn et al. , Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples, Clin Cancer Res 5(12Dec 1999), 4158-4163.
71. A. E. Ring, L. Zabaglo, M. G. Ormerod, I. E. Smith and M. Dowsett, Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques, Br J Cancer 92(514 Mar 2005), 906-912.
72. S. A. Bustin, V. Benes, T. Nolan andM. W. Pfaffl, Quantitative real-time RT-PCR-a perspective, J Mol Endocrinol 34(3Jun 2005), 597-601.
73. P. S. Bernard and C. T. Wittwer, Real-time PCR technology for cancer diagnostics, Clin Chem 48(8Aug 2002), 1178-1185.
74. R. L. Houghton, D. C. Dillon, D. A. Molesh, B. K. Zehentner, J. Xu, J. Jiang et al. , Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells, Mol Diagn 6(2Jun 2001), 79-91.
75. B. K. Zehentner, D. H. Persing, A. Deme, P. Toure, S. E. Hawes, L. Brooks et al. , Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA, Clin Chem 50(11Nov 2004), 2069-2076.
76. R. Schuster, N. Max, B. Mann, K. Heufelder, F. Thilo, J. Grone et al. , Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers, Int J Cancer 108(210 Jan 2004), 219-227.
77. K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico, Jr. et al. , Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients, Clin Chem 51(6Jun 2005), 981-988.
78. V. Choesmel, J. Y. Pierga, C. Nos, A. Vincent-Salomon, B. Sigal-Zafrani, J. P. Thiery et al. , Enrichmentmethods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance, Breast Cancer Res 6(52004), R556-R570.
79. V. Choesmel, P. Anract, H. Hoifodt, J. P. Thiery and N. Blin, A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases, Cancer 101(415 Aug 2004), 693-703.
80. T. Fehm, S. Braun, V. Muller, W. Janni, G. Gebauer, C. Marth et al. , A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation, Cancer 107(51 Sep 2006), 885-892.
81. T. J. Molloy, A. J. Bosma and L. J. Van't Veer, Towards an optimized platform for the detection, enrichment, and semiquantitation circulating tumor cells, Breast Cancer Res Treat (23 Jan 2008).
82. Y. H. Datta, P. T. Adams andW. R. Drobski, al. e. Sensitive detection of occult breast cancer by reverse-transcriptase polymerase chain reaction, J Clin Oncol 12 (1994), 475-482.
83. I. H. Benoy, H. Elst, I. Van der Auwera, S. Van Laere, P. van Dam, E. Van Marck et al. , Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer, Br J Cancer 91(1015 Nov 2004), 1813-1820.
84. A. Schoenfeld, Y. Luqmani, Y. Smith, S. O'Reilly, S. Shousha, H. D. Sinnet et al. , Detection of breast cancer micrometastases in axillary nodes using polymerase chain reaction, Cancer Res 54 (1994), 2986-2990.
85. D. S. Hoon, T. Sarantou, F. Doi, D. D. Chi, C. Kuo, A. J. Conrad et al. , Detection of metastatic breast cancer by betahCG polymerase chain reaction, Int J Cancer 69(521 Oct 1996), 369-374.
86. M. Mitas, K. Mikhitarian, C. Walters, P. L. Baron, B. M. Elliott, T. E. Brothers et al. , Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel, Int J Cancer 93 (2001), 162-171.
87. S. Noguchi, T. Aihara, K. Motomura, H. Inaji, S. Imaoka and H. Koyama, Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptasepolymerase chain reaction. Comparison betweenMUC1mRNA and keratin 19 mRNA amplification, Am J Surg Pathol 148 (1996), 649-656.
88. M. Lacroix, R. A. Toillon and G. Leclercq, p53 and breast cancer, an update, Endocr Relat Cancer 13(2Jun 2006), 293-325.
89. G. Khair, J. R. Monson and J. Greenman, Epithelialmolecular markers in the peripheral blood of patients with colorectal cancer, Dis Colon Rectum 50(8Aug 2007), 1188-1203.
90. A. J. Bosma, B. Weigelt, A. C. Lambrechts, O. J. Verhagen, R. Pruntel, A. A. Hart et al. , Detection of circulating breast tumor cells by differential expression of marker genes, Clin Cancer Res 8(6Jun 2002), 1871-1877.
91. A. Nissan, A. Jager, A. Roystacher, A. Prus, T. Peretz, I. Eisenberg et al. ,Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients, Br J Cancer 94(513 Mar 2006), 681-685.
92. M. Quintela-Fandino, J. M. Lopez, R. Hitt, S. Gamarra, A. Jimeno, R. Ayala et al. , Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support, J Clin Oncol 24(221 Aug 2006), 3611-3618.
93. W. E. Gillanders, K. Mikhitarian, R. Hebert, P. D. Mauldin, Y. Palesch, C. Walters et al. , Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multiinstitutional cohort study, Ann Surg 239(6Jun 2004), 828- 837; discussion 37-40.
94. R. L. Theriult and G. N. Hortobagy, Bone metastases in breast cancer, Anticancer Drugs 3 (1992), 455-462.
95. J. J. Body, Metastatic bone disease: clinical and therapeutic aspects, Bone 13(Suppl1992), 857-862.
96. S. Braun, F. D. Vogl, B. Naume, B. Janni, M. P. Osborne, R. C. Coombes et al. , A pooled analysis of bone marrow micrometastasis in breast cancer, N Engl J Med 353(825 Aug 2005), 793-802.
97. G. Wiedswang, E. Borgen, R. Karesen, G. Kvalheim, J. M. Nesland, H. Qvist et al. , Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer, J Clin Oncol 21(1815 September 2003), 3469-3478.
98. G. Porro, S. Menard and E. Tagliabue, al. e. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients, Cancer 61 (1988), 2407.
99. J. L. Mansi, U. Easton and J. C. Berger, al. e. Bone marrow micrometastases in primary breast cancer: prognostic significance after six years' follow-up, Eur J Cancer 27 (1991), 1552.
100. I. J. Diel, M. Kaufman and R. Goener, al. e. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastases, J Clin Oncol 10 (1992), 1534-1539.
101. I. J. Diel, M. Kaufman, S. D. Costa, R. Holle, G. von Minckwitz, E. F. Solomayer et al. , Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status, J Natl Cancer Instit 88(221996), 1652-1658.
102. D. P. Dearnaley, M. G. Ormerod and M. G. Sloane, Micrometastases in breast cancer: long-term follow-up of the first patient cohort, Eur J Cancer 27 (1991), 236.
103. S. Braun, K. Pantel, P. Muller, W. Janni, W. Hepp, W. Kentenich et al. , Cytokeratin-postive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer, N Eng J Med 342(82000), 525-533.
104. V. Drageset, J. M. Nesland, B. Erikstein, E. Skovlund, H. Sommer, G. Anker et al. , Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy, Int J Cancer (27 Dec 2005).
105. A. M. Neville, K. N. Price and R. D. Gelber, al. e. Axillary lymph node micrometastases and breast cancer, Lancet 337 (1991), 110.
106. G. H. Sakorafas, J. Geraghty and G. Pavlakis, The clinical significance of axillary lymph nodemicrometastases in breast cancer, Eur J Surg Oncol 30(8Oct 2004), 807-816.
107. G. Bussolati, P. Gugliotta and P. Morra, al. e. The immunohistochemical detection of lymph node micrometastases from infiltrating lobular carcinoma of the breast, Br J Cancer 54 (1986), 631-636.
108. J. Byrne, R. Waldron and D. McAvinchy, al. e. The use of monoclonal antibodies for the histological detection of mammary axillary micrometastases, Eur J Surg Oncol 13 (1987), 409.
109. R. J. Cote and C. R. Taylor, Immunomicroscopy: A diagnostic tool for the surgical pathologist, in: Tumors of the Breast, C. R. Taylor and R. J. Cote, eds, Philadelphia: WB Saunders, 1994, pp. 200-236.
110. C. E. Elson, D. Kufe andW. W. Johnston, Immunohistochemical detection and significance of axillary lymph node micrometastases in breast cancer- a study of 97 cases, Anal Quant Cytol Histol (1993), 171-178.
111. J. W. Pickren, Significance of occult metastases. A study of breast cancer, Cancer 14 (1961), 1266-1271.
112. E. J. Wilkinson, L. L. Hause and R. G. Hoffman, al. e. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and the significance of metastases, Path Ann 17 (1982), 67-91.
113. E. R. Fisher, S. Saminoss and C. H. Lee, al. e. Detection and significance of occult axillary node metastases in patients with invasive breast cancer, Cancer 42 (1978), 2025-2031.
114. International (LUDWIG) Breast Cancer Study Group. Prognostic importance of occult lymph node micrometastases from breast cancers, Lancet 335 (1990), 1565-1568.
115. R. J. Cote, H. F. Peterson, B. Chaiwun, R. D. Gelber, Goldhirsh, B. Castiglions-Gertsch et al. , Role of immunohistochemical detection of lymph-nodemetastases inmanagement of breast cancer, Lancet 354(91821999), 896-900.
116. I. de Mascarel, F. Bonichon, J. M. Coindre and M. Trojani, Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up, Br J Cancer 66 (1992), 523-527.
117. L. K. Tan, D. Giri, D. Hummer, D. Panageas, E. Brogi, L. Norton et al. , Occult axillary nodemetastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up, J Clin Oncol 26(1110 Apr 2008), 1803-1809.
118. E. Cristofanilli, G. T. Budd, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller et al. , Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N Engl J Med 351(819 Aug 2004), 781-791.
119. M. Cristofanilli, D. F. Hayes, G. T. Budd, M. J. Ellis, A. Stopeck, A. Reuben et al. , Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer, J Clin Oncol 23(71 Mar 2005), 1420-1430.
120. T. Bauernhofer, T. Zenahlik, T. Hofmann, T. Balic, M. Resel, M. Pirchmoser et al. , Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer, Oncol Rep 13(2Feb 2005), 179-184.
121. D. F. Hayes, M. Cristofanilli, G. T. Budd, M. J. Ellis, A. Stopeck, M. C. Miller et al. , Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival, Clin Cancer Res 12(14 Pt 115 Jul 2006), 4218-4224.
122. F. C. Bidard, A. Vincent-Salomon, A. Sigal-Zafrani, V. Dieras, C. Mathiot, L. Mignot et al. , Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells, Ann Oncol 19(3Mar 2008), 496-500.
123. C. A. Klein, S. Seidl, S. Petat-Dutter, S. Offner, J. B. Geigl, O. Schmidt-Kittler et al. , Combined transcriptome and genome nalysis of singlemicrometastatic cells, Nat Biotechnol 20(4Apr 2002), 387-392.
124. O. Schmidt-Kittler, T. Ragg, T. Daskalakis, T. Granzow, A. Ahr, T. J. Blankenstein et al. , From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression, Proc Natl Acad Sci US A 100(1324 Jun 2003), 7737-7742.
125. T. J. Schardt, M. Meyer, C. H. Hartmann, F. Schubert, O. Schmidt-Kittler, C. Fuhrmann et al. , Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer, Cancer Cell 8(3Sep 2005), 227-239.
126. D. A. Smirnov, D. R. Zweitzig, B. W. Foulk, M. C. Miller, G. V. Doyle, K. J. Pienta et al. , Global gene expression profiling of circulating tumor cells, Cancer Res 65(1215 Jun 2005), 4993-4997.
127. K. J. Heiss, K. J. Allgayer, K. J. Gruetzner, K. J. Funke, K. J. Babic, K. J. Jauch et al. , Individual development and uPAreceptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer, Nat Med 1(10Oct 1995), 1035-1039.
128. S. Braun, G. Schlimok, G. Heumos, G. Schaller, L. Riethdorf, G. Riethmuller et al. , erbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients, Cancer Research 61 (1 March 2001), 1890-1895.
129. V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz et al. , Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity, Clin Cancer Res 11(1015 May 2005), 3678-3685.
130. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A 100(71 Apr 2003), 3983-3988.
131. L. Hebbard, A. Steffen, V. Zawadzki, C. Fieber, N. Howells, N. Moll et al. , CD44 expression and regulation during mammary gland development and function, J Cell Sci 113(Pt 14Jul 2000), 2619-2630.
132. J. E. Draffin, S. McFarlane, A. Hill, P. G. Johnston and D. J. Waugh, CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells, Cancer Res 64(1615 Aug 2004), 5702-5711.
133. H. Schabath, S. Runz, S. Joumaa and P. Altevogt, CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells, J Cell Sci 119(Pt 215 Jan 2006), 314-325.
134. S. Paget, The distribution of secondary growths in cancer cells of the breast, Lancet 1 (1989), 571-573.
135. F. C. Bidard, J. Y. Pierga, A. Vincent-Salomon and M. F. Poupon, A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev 27(1Mar 2008), 5-10.
136. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal et al. , Cancer statistics, CA Cancer J Clin 56(2Mar-Apr 2006), 106-130.
137. E. D. Bernstein, S. M. Herbert and N. H. Hanna, Chemotherapy and radiotherapy in the treatment of resectable non-smallcell lung cancer, Ann SurgOncol 13(3Mar 2006), 291-301.
138. J. D. Minna, H. Pass, E. J. Gladstein and D. C. Ihde, Cancer of the lung, in: Cancer, Principles and Practice of Oncology, V. T. DeVita, S. Hellman and S. A. Rosenberg, eds, Philadelphia: J. B. Lippincott, 1989, pp. 591-705.
139. E. C. Rosenow and D. T. Carr, Bronchogenic carcinoma, Ca Cancer J Clin 29 (1979), 233-246.
140. E. C. Beahrs, D. E. Henson, R. V. P. Hutter and M. H. Myers, American Joint Committee in Cancer Manual for Staging Cancer, (3rd ed. ), Philadelphia: J. B. Lippincott, 1988.
141. C. F. Mountain, The international system for staging lung cancer, Semin Surg Oncol 18(2Mar 2000), 106-115.
142. T. Osaki, T. Oyama, C. -D. Gu, T. Yamashita, T. So, M. Takenoyama et al. , Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer, J Clin Oncol 20(131 July 2002), 2930-2936.
143. A. Ohgami, M. Tetsuya and S. Kenji, al. e. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer, Ann Thorac Surg 64 (1997), 363-367.
144. K. Yasumoto, T. Osaki, Y. Watanabe, H. Kato and T. Yoshimura, Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study, Ann Thorac Surg 76(1Jul 2003), 194-201; discussion 2.
145. P. F. Brunsvig, K. Flatmark, S. Aamdal, H. Hoifodt, H. Le, E. Jakobsen et al. , Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients, Lung Cancer 61(2Aug 2008), 170-176.
146. W. Sienel, I. Mecklenburg, S. Dango, P. Ehrhardt, A. Kirschbaum, B. Passlick et al. , Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer, Clin Cancer Res 13(131 Jul 2007), 3840-3847.
147. F. Pasini, F. Pelosi, G. Verlato, G. Guidi, F. Pavenel, D. Tummarello et al. , Positive immunostaining with MuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer, Annal Oncol 9 (1998), 181-185.
148. Z. L. Chen, S. Perez, E. C. Holmes, H. -J. Wang, W. F. Coulson, D. -R. Wen et al. , Frequency and distribution of occult micrometastases in lymph node of patients with non-small cell lung cancer, J Natl Cancer Inst 85 (1993), 493-498.
149. B. Passlick, J. R. Izbicki and B. Kubuschak, al. e. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small cell lung lung cancer, J Clin Oncol 12 (1994), 1827-1832.
150. U. Latza, G. Niedobitek and R. Schwarting, al. e. New monoclonal antibody which distinguishes epithelia from mesothelia, J Clin Path 43 (1990), 213-219.
151. S. B. Hosch, P. Scheunemann and J. R. Izbicki, Minimal residual disease in non-small-cell lung cancer, Semin Surg Oncol 20(4Jun 2001), 278-281.
152. C. Tezel, A. A. Ersev, H. Kiral, S. Urek, A. Kosar, M. Keles et al. , The impact of immunohistochemical detection of positive lymph nodes in early stage lung cancer, Thorac Cardiovasc Surg 54(2Mar 2006), 124-128.
153. M. J. Ge, Q. C. Wu, M. Wang, Y. H. Zhang and L. B. Li, Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance, J Cancer Res Clin Oncol 131(10Oct 2005), 662-668.
154. X. T. Wang, W. Sienel, S. Eggeling, C. Ludwig, E. Stoelben, J. Mueller et al. , Detection of disseminated tumor cells inmediastinoscopic lymph node biopsies and lymphadenectomy specimens of patients with NSCLC by quantitative RT-PCR, Eur J Cardiothorac Surg 28(1Jul 2005), 26-32.
155. L. Xi, M. C. Coello, V. R. Litle, S. Raja, W. E. Gooding, S. A. Yousem et al. , A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients, Clin Cancer Res 12(815 Apr 2006), 2484-2491.
156. S. Bracarda, O. de Cobelli, C. Greco, T. Prayer-Galetti, R. Valdagni, G. Gatta et al. , Cancer of the prostate, Crit Rev Oncol Hematol 56(322 Nov 2005), 379-396.
157. J. A. Clifton, R. J. Phillip, E. Ludovic andW. M. Fowler, Bone marrow and carcinoma of the prostate, Am J Med Sci 224 (1952), 121-130.
158. C. M. K. Nelson, D. L. Boatman and R. H. Flocks, Bone marrow examination in carcinoma of the prostate, J Urol 109 (1973), 667-670.
159. J. L. Mansi, U. Berger, P. Wilson, R. Shearer and R. C. Coombes, Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques, J Urol 139 (1988), 545-548.
160. J. Kollermann, S. Weikert M. Schostak, C. Kempkensteffen, K. Kleinschmidt, T. Rau et al. , Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment, J Clin Oncol 26(3020 Oct 2008), 4928-4933.
161. D. P. J. Wood, E. R. Banks, S. Humphreys, J. W. McRoberts andM. angnekar, Identification of bone marrow micrometastases in patients with prostate cancer, Cancer 74 (1 Nov 1994), 2533-2540.
162. A. E. Katz, al. e. Molecular staging of prostate cancer with the use of an enhanced reverse-transcriptase polymerase chain reaction assay, Urology 43 (1994), 765-775.
163. R. S. Israeli, W. H. Miller, S. L. Su, C. T. Powell, W. R. Fair, W. R. Samadi et al. , Sensitive nested reverse transcriptase polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate specific membrane antigen and prostate specific antigen based assays, Cancer Res 54(2415 Dec 1994), 6306-6310.
164. W. R. Gao, R. C. Dean, A. Pinto, R. Mooneyhan, R. R. Connelly, D. G. McLeod et al. , Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction, J Urol 161(4Apr 1999), 1070-1076.
165. M. R. Smith, S. Biggar and M. Hussain, Prostate-specific antigen messanger RNA is expressed in non-prostate cells: implications for detection of micrometastases, Cancer Res 55(1215 Jun 1995), 2640-2644.
166. F. J. Bianco, Jr. , D. P. Wood, Jr. , J. Gomes de Oliveira, J. A. Nemeth, A. A. Beaman and M. L. Cher, Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer, Prostate 49(41 Dec 2001), 235-242.
167. J. A. Freeman, G. Lieskovsky, D. W. Cook, Z. Petrovich, C. S and D. G. Skinner, Radical retropubic prostatectomy and post-operative radiation for pathologic stage C (PCN0) prostate cancer from 1976-1989: intermediate findings, J Urol 149 (1993), 1029.
168. L. G. Gomella, J. L. White, P. A. McCue, D. S. Byrne and S. G. Mulholland, Screening for occult nodal metastasis in localized carcinoma of the prostate, J Urol 149 (1993), 776.
169. H. J. Gross, B. Verwer, D. Houck, R. A. Hoffman and D. Recketenwald, Model study detecting breast cancer cells in eripheral blood mononuclear cells at frequencies as low as 10-7, Proc Natl Acad Sci USA 92 (1995), 537-541.
170. J. W. Moul, D. J. Lewis, A. A. Ross, D. G. Kahn, C. H. Ho and D. G. McLeod, Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to pre-operative serum prostate-specific antigen, Urology 43 (1994), 68.
171. G. R. J. Prout, J. A. Heaney, P. P. Griffith, J. J. Daly and W. U. Shipley, Nodal involvement as a prognostic indicator in patients with prostatic carcinoma, J Urol 124 (1980), 226.
172. V. Pagliarulo, D. Hawes, F. H. Brands, S. Groshen, J. Cai, J. P. Stein et al. , Detection of Occult Lymph NodeMetastases in Patients with Locally Advanced (pT3) Node-Negative Prostate Cancer, J Clin Oncol (2006), in press.
173. D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka et al. , Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer, Clin Cancer Res 13(231 Dec 2007), 7053-7058.
174. J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing et al. , Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res 14(191 Oct 2008), 6302-6309.
175. D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu et al. , Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer, Clin Cancer Res 13(71 Apr 2007), 2023-2029.
176. M. Gerhard, H. Juhl, H. Kalthoff, H. W. Schreiber, C. Wegener and M. Neumaier, Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction, J Clin Oncol 12 (1994), 725-729.
177. H. Juhl, M. Stritzel and A. Wroblewski, al. e. Immunocytochemical detection of micrometastatic cells: comparative evalution of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients, Int J Cancer 57 (1994), 330-335.
178. G. C. O'Sullivan, J. K. Collins, J. Kelly, J. Morgan, M. Madden and F. Shanahan, Micrometastases: marker of metastatic potential or evidence of residual disease? Gut 40(4Apr 1997), 512-515.
179. E. Soeth, I. Vogel, C. Roder, H. Juhl, J. Marxsen, U. Kruger et al. , Comparative analysis of bone marrow and venous blood isolates fromgastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR, Cancer Res 57(151 Aug 1997), 3106-3110.
180. J. Weitz, M. Koch, P. Kienle, A. Schrodel, F. Willeke, A. Benner et al. , Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer, Ann Surg 232(1Jul 2000), 66-72.
181. S. Leinung, P. Wurl, A. Schonfelder, C. L. Weiss, I. Roder and M. Schonfelder, Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis, J Hematother Stem Cell Res 9(6Dec 2000), 905-911.
182. K. Flatmark, K. Bjornland, H. O. Johannessen, E. Hegstad, R. Rosales, L. Harklau et al. , Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients, Clin Cancer Res 8(2Feb 2002), 444-449.
183. A. M. Cohen, P. Garin-Chesa, M. Hanson, K. Weyhrauch, N. Kemeny, N. Fong et al. , In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases, Dis Colon Rectum 41(9Sep 1998), 1112-1115.
184. K. Schoppmeyer, N. Fruhauf, K. Oldhafer, S. Seeber and S. Kasimir-Bauer, Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases, Oncol Rep 15(2Feb 2006), 449-454.
185. A. Schott, I. Vogel, I. Krueger, H. Kalthoff, H. W. Schreiber, W. Schmiegel et al. , Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker, Ann Surg 227(3Mar 1998), 372-379.
186. R. Steinert, M. Hantschick, M. Vieth, I. Gastinger, F. Kuhnel, H. Lippert et al. , Influence of subclinical tumor spreading on survival after curative surgery for colorectal cancer, Arch Surg 143(2Feb 2008), 122-128.
187. S. Riethdorf, H. Wikman and K. Pantel, Review: Biological relevance of disseminated tumor cells in cancer patients, Int J Cancer 123(91 Nov 2008), 1991-2006.
188. F. L. Greene, Staging of colon and rectal cancer: from endoscopy tomolecularmarkers, Surg Endosc 20(Suppl 2Apr 2006), S475-S478.
189. C. Mescoli, M. Rugge, S. Pucciarelli, V. M. Russo, G. Pennelli, M. Guido et al. , High prevalence of isolated tumor cells in regional lymph nodes from PN0 colorectal cancer, J Clin Pathol (7 Apr 2006).
190. R. Cutait, V. A. F. Alves, L. C. Lopez, D. E. Cutait, J. L. A. Borges, J. Singer et al. , Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins, Dis Colon Rectum 34 (1991), 917-922.
191. M. D. Jeffers, G. M. O'Dowd, H. Mulcahy, M. Stagg, D. P. O'Donoghue and M. Toner, The prognostic significance of mmunohistochemically detected lymph node micrometastases in colorectal cancer, J Pathol 172 (1994), 183-187.
192. B. Florentine, B. Ettekal, C. G. Leichman, W. Naritou, P. Nichols, S. Groshen et al. , Prognostic importance of occult lymph node metastases detected by cytokeratin immunohistochemical techniques in stage II colon cancer, Proceedings of ASCO Abstract (1996).
193. J. K. Greenson, C. E. Isenhart and R. Rice, al. e. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratins and CC49, Cancer 73 (1994), 563-569.
194. A. J. Bilchik, D. S. Hoon, S. Saha, R. R. Turner, D. Wiese, M. DiNome et al. , Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial, Ann Surg 246(4Oct 2007), 568-575; discussion 75-77.
195. A. E. Bembenek, R. Rosenberg, E. Wagler, S. Gretschel, A. Sendler, J. R. Siewert et al. , Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial, Ann Surg 245(6Jun 2007), 858-863.
196. A. Stojadinovic, A. Nissan, A. Protic, C. F. Adair, D. Prus, S. Usaj et al. , Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01, Ann Surg 245(6Jun 2007), 846-857.